| Literature DB >> 19471197 |
Jang-Gi Choi1, Ok-Hwa Kang, Young-Seob Lee, You-Chang Oh, Hee-Sung Chae, Hye-Jin Jang, Dong-Won Shin, Dong-Yeul Kwon.
Abstract
Methyl gallate is a major component of Galla Rhois, as carvacrol is of oregano essential oils. Both have shown good antibacterial activity against intestinal bacteria. This study investigated the antibacterial activities of nalidixic acid in combination with methyl gallate and carvacrol against nalidixic acid resistant bacteria. The combined effect of nalidixic acid with methyl gallate and carvacrol was evaluated using the checkerboard method to obtain a fractional inhibitory concentration index. The results showed that the combinations of nalidixic acid + methyl gallate/carvacrol improved nalidixic acid resistant pathogenic bacteria inhibition with synergy or partial synergy activity. Thus, a strong bactericidal effect of the drug combinations was observed. In vitro data thus suggested that nalidixic acid combined with methyl gallate and carvacrol may be microbiologically beneficial, rather than antagonists.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19471197 PMCID: PMC6254153 DOI: 10.3390/molecules14051773
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Result of the combined effect of methyl gallate (MG) and nalidixic acid (NA) againstnalidixic acid-resistant pathogenic bacteria.
| Strain | Serotypes | a) MIC MG | MIC NA | b) FICI | ||
|---|---|---|---|---|---|---|
| Alone (µg/mL) | With NA (µg/mL) | Alone (µg/mL) | With MG (µg/mL) | |||
| CCARM 1 | NR- | 250 | 125 | 250 | 15.6 | 0.56 |
| CCARM 2 | NR- | 250 | 125 | 250 | 15.6 | 0.56 |
| CCARM 3 | NR- | 500 | 125 | 500 | 31.25 | 0.31 |
| CCARM 4 | NR- | 250 | 125 | 250 | 62.5 | 0.75 |
| CCARM 5 | NR- | 500 | 250 | 500 | 31.25 | 0.56 |
| CCARM 6 | NR- | 250 | 500 | 250 | 62.5 | 2.25 |
| CCARM 7 | NR- | 1000 | 500 | 250 | 15.6 | 0.56 |
| CCARM 8 | NR- | 250 | 125 | 500 | 31.25 | 0.56 |
a) MIC, Minimum inhibitory concentration; b) FICI, fractional inhibitory concentration index.
Result of the combined effect of carvacrol (CA) and nalidixic acid (NA) against nalidixic acid-resistant pathogenic bacteria.
| Strain | Serotypes | a) MIC CA | MIC NA | b) FICI | ||
|---|---|---|---|---|---|---|
| Alone (µg/mL) | With NA (µg/mL) | Alone (µg/mL) | With CA (µg/mL) | |||
| CCARM 1 | NR- | 250 | 31.25 | 250 | 31.25 | 0.25 |
| CCARM 2 | NR- | 250 | 62.5 | 250 | 500 | 2.25 |
| CCARM 3 | NR- | 250 | 62.5 | 500 | 31.25 | 0.31 |
| CCARM 4 | NR- | 250 | 31.25 | 250 | 31.25 | 0.25 |
| CCARM 5 | NR- | 500 | 125 | 500 | 15.6 | 0.28 |
| CCARM 6 | NR- | 500 | 31.25 | 250 | 15.6 | 0.12 |
| CCARM 7 | NR- | 125 | 62.5 | 250 | 250 | 1.5 |
| CCARM 8 | NR- | 500 | 250 | 500 | 500 | 1.5 |
a) MIC, Minimum inhibitory concentration; b) FICI, fractional inhibitory concentration index.
Antibacterial activity of nalidixic acid (NA), nalidixic acid (NA) + methyl gallate (MG), nalidixic acid (NA) + carvacrol (CA), and norfloxacin (NO) againstnalidixic acid-resistant pathogenic bacteria (NR).
| Strain | Serotypes | a) MIC (µg/mL) | |||
|---|---|---|---|---|---|
| NA | NA+MG | NA+CA | b) NO | ||
| CCARM 1 | NR- | 250 | 15.6 | 31.25 | 0.97 |
| CCARM 2 | NR- | 250 | 15.6 | 500 | 0.03 |
| CCARM 3 | NR- | 500 | 31.25 | 31.25 | 0.97 |
| CCARM 4 | NR- | 250 | 62.5 | 31.25 | 1.97 |
| CCARM 5 | NR- | 500 | 31.25 | 15.6 | 1.97 |
| CCARM 6 | NR- | 250 | 62.5 | 15.6 | 1.97 |
| CCARM 7 | NR- | 250 | 15.6 | 250 | 1.97 |
| CCARM 8 | NR- | 500 | 31.25 | 500 | 3.9 |
a) MIC, Minimum inhibitory concentration; b) Positive control.
ΣFIC values and number of nalidixic acid-resistant pathogenic bacteria showing synergy, partial synergy or indifference with methyl gallate (MG) + nalidixic acid (NA) and carvacrol (CA) + nalidixic acid (NA) combinations.
| Combination | a) ΣFICI | No. of strains showing | ||||
|---|---|---|---|---|---|---|
| Range | Median | Synergy (%) | Partial Synergy (%) | Additive (%) | Indifference (%) | |
| MG+NA | 0.31~2.25 | 0.76 | 1 | 6 | 0 | 1 |
| Total | 1/8 (12.5) | 6/8 (75) | 0 | 1/8 (12.5) | ||
| CA+NA | 0.12 ~2.25 | 0.77 | 5 | 0 | 0 | 3 |
| Total | 5/8 (62.5) | 0 | 0 | 3/8 (37.5) | ||
a) FICI, fractional inhibitory concentration index.